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OBJECTIVES: Several studies have shown that traditional statistical measures of
association and agreement are not able to capture relevant appreciation of physi-
cian-patient relationship. Literature has shown evidence of miscommunication
between: a) members of multidisciplinary team; b) teams and specialized care; and
c) health care and user. The aim of study was to evaluate the properties of corre-
spondence analysis technique, describing the viewpoint of health professionals on
multidisciplinary teamwork and interaction with specialty assistance, and its con-
tribution for shared decision-making process. METHODS: Cross sectional, descrip-
tive study using a questionnaire, was applied in a face-to-face interview. A pilot
questionnaire seeking improvement for sample calculation was conducted. We
used descriptive analysis to map the results. Multiple correspondence analyses
were performed to explore the outcomes and assumptions established. RESULTS:
We interviewed 78 health professionals, 50% Caucasian, 82.5% female, mean age
was 36.97 yrs (min. 22; max. 70, SD: 9.98). Participants were physicians (12.82%);
nurses (14.1%); nurse technicians (25.64%); dentist (12.82%), dentist technicians
(8.97%) and health assistance technicians (8.97%). Correspondence analysis plot
illustrated that a multiprofessional team can improve patient’s knowledge about
their diseases and treatments and it can be a strategy for shared decision-making
approach. However, for multiprofessional team maintenance, professional roles
and responsibilities must be well defined. Regarding primary and specialty care
communication, the plots showed that primary care usually refers patients to a
specialist more than is needed, because they have low abilities to manage complex
diseases. The willingness for shared decision-making approach is low due to high
number of patients which they have to assist on primary care. CONCLUSIONS:
Correspondence analysis suggested that multiprofessional team was involved on
the process of health decision-making, which can improve the patient participa-
tion. However, roles and responsibilities must be clearly defined. These points can
derive assumptions for shared decision-making approach and for strategies to its
implementation on clinical practice.
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OBJECTIVES: There were several pricing and reimbursement policy (P&R) restric-
tions introduced in Slovakia during last 5 years, including new reimbursement law
valid from 1 December 2011. The objective of the review is to evaluate the impact of
policy restrictions and assess their future impact on the access to new medicines.
METHODS: Based on the legal framework, development of P&R policy and its im-
pact on the drug expenditures and consumption was evaluated. The level of reim-
bursement by Health Insurance companies and consumption of medicines were
taken from official database sources. Officially published MoH reimbursement de-
cisions were analysed, particularly in relation to the assessment of pharmacoeco-
nomic submissions. RESULTS: During the last five years several cost containment
measures were implemented in P&R policy (reference pricing, flat price decrease,
VAT change, digressive margin, health economic evaluation guidance). As a result
Slovakia reached sustainable drug expenditures during last three years. Despite of
restrictions, the availability of innovative treatments is still comparable to other
CEE countries. The new reimbursement law defines new requirements for setting
of P&R. Some of them will have serious impact on reimbursement of new drugs and
access to them (second lowest price within EU, price set in at least five EU countries,
cost/QALY threshold, reimbursement level measured by defined clinical advan-
tages, etc.). During the last evaluation in June 2012, new drugs for metastatic mel-
anoma, metastatic prostate cancer and metastatic breast cancer were refused as
well as 4 new indications, due to non-compliance with the law requirements.
CONCLUSIONS: The P&R policy in Slovakia has gone through several changes in
last five years. The new legislation can dramatically influence the P&R approval of
new, particularly high priced medicines. This will challenge payers, health care
providers, industry and patients to find new ways to maintain the availability of
innovative treatment in Slovakia.
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OBJECTIVES: Recent reviews have examined differences in PRO label claims com-
paring U.S Food and Drug Administration (FDA) decisions to those in the European
Medicines Agency (EMA). Limited research has been conducted to identify where
there is concordance between agency decisions in PRO labeling. This analysis
sought to discover instances where similar PRO labels were granted by each agency
to determine if there are precipitating factors that would increase the likelihood of
claims being granted by both. METHODS: AA listing of drug approvals granted by
both the FDA and EMA was generated, identifying a total of 75 products (2006-2010).
PRO claims found in US Drug Approval Packages and European Public Assessment
Reports packages were compared to detect any similarities or differences in claims
made for the same product by the same company. For analysis purposes, PRO claim
type was categorized as symptoms, functioning, HRQOL, patient global rating
(PGR), or other. RESULTS:A total of 75 products were approved by both agencies. Of
these, a total of 35 (47%) were granted at least one PRO claim by the EMA as com-
pared to 14 (19%) by the FDA. Of the 14 products with PRO claims granted by both
agencies, only a small number (n4, 11%) had the same claim types granted, with-
out deviation. Despite these discrepancies, upon dissection of the labels, common-
alities were identified. Symptom claims were granted in 12 of 14 products by both
agencies as were 5 functioning and 3 PGR claims. CONCLUSIONS: While PRO label
claims do not demonstrate perfect agreement between agencies, upon close exam-
ination there appears to be greater concordance then previously recognized. Pre-
cipitating factors such as therapeutic area, PRO measure or order of regulatory
submission may influence the agreement between agencies. Further investigation
is warranted to better support effective PRO strategies.
PHP183
THE ROCKY ROAD TO MARKET EQUILIBRIUM – PRICE REGULATION AND ENTRY
LIBERALIZATION IN PORTUGUESE RETAIL PHARMACY
Barros PP1, Martins B2, Moura A2
1Nova School of Business and Economics, Lisbon, Portugal, 2Nova School of Business and
Economics, Lisboa, Lisboa, Portugal
OBJECTIVES: In the last years, several measures in the Portuguese pharmaceutical
sector were adopted aimed at decreasing pharmaceutical prices and profit margins
of pharmacies. Since both prices and profit margins are regulated, pharmacies are
not able to react to these changes by changing prices. The political and economic
case for these measures was made based on economic models od the pharmaceu-
tical distribution, based on econometric estimations cost functions and their im-
plications for market equilibria. The policy advocacy was made first in 2005, using
information from 2002. Today, the sector faces a different reality. Results based on
2002 data potentially are outdated. METHODS: This paper estimates the cost func-
tion for the Portuguese pharmacies and its implications towards the policy-mea-
sures taken in the last years. We use individual information from 1 346 pharmacies
for the year 2010, enlarging considerably previous studies in terms of observations
and updating to more recent data. We also study the effect of price and entry
liberalization policies, using simulations from a theoretical model with spatial
competition. RESULTS: Our results show that the cost structure for Portuguese
pharmacies changed drastically from 2002 to 2010. Indeed, while the marginal cost
decreased by 6.6%, the fixed cost increased by 91.3%, resulting in an increase in the
economies of scale. Therefore, pharmacies need higher profits margins in order to
be able to have nonnegative profits. Our simulations show that price liberalization
(with regulated entry) would result in negative profits, contrary to what would
happen in 2002. CONCLUSIONS: Price policies that focus only in the marginal cost,
as has been happening so far, may not be adequate to ensure the sustainability of
the retail pharmaceutical sector, as they do not account for fixed costs. New poli-
cies should reflect the relation between the price and the average cost, rather than
the marginal, whenever prices are administratively decreased.
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OBJECTIVES: In May 2011, the Portuguese government signed a Memorandum of
Understanding with the EC, ECB and IMF as part of a financial rescue program. Part
of the program involved a reduction of € 50M in the public expenditure with phar-
maceuticals. One specific measure introduced a new margin scheme to pharma-
cies (and distributors), consisted of an increasing fixed fee and a regressive margin
as a percentage of the ex-factory price, making prices lower in general. Prior to this
margin scheme, a linear system was in place. This measure will clearly affect the
pharmaceutical retail sectors, with a decrease in the pharmacies’ profits. In this
study we assess the impact of the several measures aimed at decreasing pharma-
ceutical expenditure on the profitability of the Portuguese pharmacies, namely
administrative and voluntary price reductions and if pharmacies can support the
change in the margin scheme.METHODS:We use a sample of 383 pharmacies, with
data from the sales of each different transaction. The time span considers the
period from January to May in both 2011 and 2012. RESULTS: Using transaction-
level data, the analysis allows for the simulation of new and old margins, keeping
consumption constant. Estimates regarding savings for patients and for payers
(mainly the National Health Service), and impact on retail and wholesale distribu-
tors can be traced. In particular, we address issues such as whether small pharma-
cies are harder hit than large ones, and whether particular groups of patients (eg.
Old pensioneers) benefit more or less than the majority of the population. Due to
the new margins design, patients benefit, though payers (especially the National
Health Service) also benefit. CONCLUSIONS: The new remuneration system is
likely to produce the expected savings. Special attention should be given to harder-
hit pharmacies and patient access to medicines and pharmacy services.
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